Preferred Label : nintedanib;

MeSH note : Boehringer Ingelheim's triple kinase inhibitor blocking VEGFR, PDGFR and FGFR;

CISMeF synonym : BIBF 1120; vargatef;

MeSH hyponym : BIBF1120; BIBF-1120;

Related MeSH term : intedanib;

MeSH CAS label : METHYL (3Z)-3-(((4-(N-METHYL-2-(4-METHYLPIPERAZIN-1-YL)ACETAMIDO)PHENYL)AMINO)(PHENYL)METHYLIDENE)-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE;

MeSH Related Number : nintedanib esylate; 42F62RTZ4G;

Related CAS MeSH : 42F62RTZ4G (Nintedanib esylate);

Is substance : O;

UNII : G6HRD2P839;

InChIKey : XZXHXSATPCNXJR-ZIADKAODSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3225386/fr/ofev-pid
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
nintedanib
administration, oral
enzyme inhibitors
protein-tyrosine kinases
lung diseases, interstitial
guidelines for drug use
chronic disease
progressive fibrosing interstitial lung disease
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
nintedanib
indoles

---
https://www.has-sante.fr/jcms/p_3225416/fr/ofev-pid-scs-chez-l-adulte
2021
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
nintedanib
enzyme inhibitors
protein-tyrosine kinases
administration, oral
adult
lung diseases, interstitial
scleroderma, systemic
nintedanib
interstitial lung disease associated with systemic sclerosis
Tyrosine Kinase Inhibitors
indoles

---
OFEV (nintedanib) - Risk of Drug-Induced Liver Injury and the Need for Regular Monitoring of Liver Function
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65670a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
administration, oral
nintedanib
nintedanib
drug monitoring
continuity of patient care
Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury
liver function tests
transaminases
bilirubin
idiopathic pulmonary fibrosis
nintedanib esylate
indoles

---
http://orbi.ulg.ac.be/handle/2268/210429
2017
false
false
false
Belgium
French
idiopathic pulmonary fibrosis
nintedanib
journal article
clinical trials, phase iii as topic
treatment outcome
administration, oral
enzyme inhibitors
quality of life
idiopathic pulmonary fibrosis
nintedanib
enzyme inhibitors
belgium
insurance, health, reimbursement
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
indoles
indoles

---
http://www.conseil-scientifique.public.lu/fr/publications/oncologie/nintedanib.html
2016
false
false
true
Luxembourg
French
guidelines for drug use
nintedanib
antineoplastic agents
protein-tyrosine kinases
protein kinase inhibitors
neoplasm metastasis
Stage IV Lung Adenocarcinoma AJCC v7
administration, oral
antineoplastic combined chemotherapy protocols
treatment outcome
survival analysis
Progression-Free survival
Tyrosine Kinase Inhibitors
nintedanib
indoles
disease-free survival
adenocarcinoma
lung neoplasms
taxoids
Docetaxel
Adenocarcinoma of Lung

---
http://www.has-sante.fr/portail/jcms/c_2038122/fr/ofev
http://www.has-sante.fr/portail/jcms/c_2038122/fr/ofev-nintedanib-inhibiteur-des-tyrosines-kinases
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
insurance, health, reimbursement
nintedanib esylate
nintedanib esylate
idiopathic pulmonary fibrosis
adult
orphan drug production
enzyme inhibitors
enzyme inhibitors
protein-tyrosine kinases
guidelines for drug use
nintedanib
Tyrosine Kinase Inhibitors
nintedanib
nintedanib
indoles
indoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Ofev
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
nintedanib
nintedanib
orphan drug production
adult
drug approval
europe
idiopathic pulmonary fibrosis
administration, oral
enzyme inhibitors
enzyme inhibitors
protein-tyrosine kinases
risk management
drug monitoring
nintedanib
lung diseases, interstitial
interstitial lung disease associated with systemic sclerosis
progressive fibrosing interstitial lung disease
Tyrosine Kinase Inhibitors
indoles
indoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Vargatef
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
nintedanib
nintedanib
drug approval
europe
antineoplastic agents
antineoplastic agents
adult
carcinoma, non-small-cell lung
neoplasm metastasis
adenocarcinoma
antineoplastic combined chemotherapy protocols
administration, oral
enzyme inhibitors
enzyme inhibitors
aged
drug interactions
pregnancy
contraception
breast feeding
protein-tyrosine kinases
drug evaluation, preclinical
nintedanib
Tyrosine Kinase Inhibitors
indoles
indoles
taxoids
Docetaxel

---
http://www.has-sante.fr/portail/jcms/c_2048057/fr/vargatef
http://www.has-sante.fr/portail/jcms/c_2048057/fr/vargatef-nintedanib-inhibiteur-de-tyrosine-kinase
2015
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
nintedanib
nintedanib
nintedanib esylate
nintedanib esylate
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
adenocarcinoma
carcinoma, non-small-cell lung
adult
neoplasm metastasis
Locally Advanced Malignant Neoplasm
neoplasm recurrence, local
insurance, health, reimbursement
enzyme inhibitors
enzyme inhibitors
receptors, fibroblast growth factor
receptors, platelet-derived growth factor
receptors, vascular endothelial growth factor
nintedanib
guidelines for drug use
Tyrosine Kinase Inhibitors
indoles
indoles

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.